Join the club for FREE to access the whole archive and other member benefits.

Robert J. Hariri

Surgeon, biomedical scientist and serial entrepreneur in biomedicine and aerospace

Bob Hariri is a surgeon, biomedical scientist and highly successful serial entrepreneur in two technology sectors: biomedicine and aerospace. The Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics, one of the world’s largest human cellular therapeutics companies, Dr. Hariri has pioneered the use of stem cells to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering.

His activities and experience includes academic neurosurgeon at Cornell, businessman, military surgeon and aviator and aerospace innovator. Dr. Hariri has over 90 issued and pending patents, has authored over 100 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered the physiological activities of TNF (tumor necrosis factor).

 robert-hariri-md-phd-78a76912

See also: Company Celularity - Cell therapeutics company

Details last updated 11-Jan-2020

Robert J. Hariri is also referenced in the following:

Regenerative Medicine and Longevity

29-Jul-2021

Dr. Robert Hariri speaks about advances in immunotherapy and regenerative medicine in live AMA with Sergey Young

Robert J. Hariri News

Celularity and Versea Ophthalmics to commercialize ophthalmic allografts

Celularity and Versea Ophthalmics to commercialize ophthalmic allografts

Celularity - 27-Jul-2023

Innovative BIOVANCE single- and three-layer products for ocular surface disease treatment & surgical support

FDA gives the green light for human trials against a new coronavirus therapy

FDA gives the green light for human trials against a new coronavirus therapy

WebMD - 03-Apr-2020

May cause serious adverse effects if stem cells over attack normal lung cells

Placental stem cell derived NK cells are effective against multiple myeloma

Placental stem cell derived NK cells are effective against multiple myeloma

Myeloma Research News - 08-Jan-2020

Preliminary results from Phase 1 trial look promising

Peter Diamandis launches new $250 million stem cells company

Peter Diamandis launches new $250 million stem cells company

TechCrunch - 15-Feb-2018

Celularity is a spinout from Celgene, a global biopharmaceutical company. Hopes to use stem cell...

Exponential Medicine conference day 3 summary

Exponential Medicine conference day 3 summary

Medgadget - 13-Nov-2015

Practice of medicine needs to become the science of medicine Regenerative and Rejuvenative Medic...